Drug Trial Radar · NCT01160770
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome
Last checked: Nov 19, 2026Latest source record: Mar 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
267
Actual
Start
Dec 2005
Primary completion
Feb 2012
Study completion Feb 2012
Sponsor
- Lead sponsor
- Lundbeck LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 12, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the long-term safety and effectiveness of open-label clobazam in the treatment of drop seizures in subjects with LGS.
Conditions
- Lennox-Gastaut Syndrome
Interventions
ClobazamDrug
Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day AssessmentTime frame: Baseline to month 36
- Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the Last 30-day AssessmentTime frame: Baseline to month 36
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.